Statistical measures of agreement between DAS28-CRP, DAS28-ESR and SDAI (remission <2.6 and LDA ≤3.2)
| Study | Proportion of remission or LDA* n/N (%) | Proportion of discordance n/N (%) | κ Coefficient† | ||||||
|---|---|---|---|---|---|---|---|---|---|
| DAS28-CRP | DAS28-ESR | SDAI | DAS28-CRP vs DAS28-ESR | SDAI vs DAS28-CRP | SDAI vs DAS28-ESR | DAS28-CRP vs DAS28-ESR | SDAI vs DAS28-CRP | SDAI vs DAS28-ESR | |
| Remission | |||||||||
| ETN plus MTX groups | |||||||||
| PRESERVE‡ (week 36) | 523/826 (63) | 525/826 (64) | 196/826 (24) | 136/826 (17) | 327/826 (40) | 351/826 (43) | 0.65 | 0.31 | 0.26 |
| COMET (week 52) | 148/265 (56) | 132/265 (50) | 59/261 (23) | 40/265 (15) | 91/261 (35) | 83/261 (32) | 0.70 | 0.35 | 0.37 |
| TEMPO (week 52) | 104/229 (45) | 88/229 (38) | 46/229 (20) | 30/229 (13) | 58/229 (25) | 48/229 (21) | 0.73 | 0.46 | 0.51 |
| APPEAL (week 16) | 82/197 (42) | 31/197 (16) | 20/197 (10) | 51/197 (26) | 62/197 (32) | 29/197 (15) | 0.42 | 0.27 | 0.35 |
| LARA (week 24) | 98/279 (35) | 70/279 (25) | 30/279 (11) | 48/279 (17) | 68/279 (24) | 52/279 (19) | 0.60 | 0.36 | 0.39 |
| MTX groups | |||||||||
| COMET (week 52) | 90/263 (34) | 73/263 (28) | 26/253 (10) | 31/263 (12) | 63/253 (25) | 48/253 (19) | 0.73 | 0.34 | 0.42 |
| TEMPO (week 52) | 54/228 (24) | 39/228 (17) | 11/228 (5) | 35/228 (15) | 43/228 (19) | 30/228 (13) | 0.53 | 0.28 | 0.35 |
| DMARD plus MTX groups | |||||||||
| APPEAL (week 16) | 22/103 (21) | 8/103 (8) | 3/103 (3) | 16/103 (16) | 19/103 (18) | 7/103 (7) | 0.40 | 0.20 | 0.34 |
| LARA (week 24) | 8/142 (6) | 5/142 (4) | 5/142 (4) | 5/142 (4) | 3/142 (2) | 6/142 (4) | 0.60 | 0.76 | 0.38 |
| LDA | |||||||||
| ETN plus MTX groups | |||||||||
| PRESERVE‡ (week 36) | 671/826 (81) | 677/826 (82) | 672/826 (81) | 74/826 (9) | 49/826 (6) | 87/826 (11) | 0.70 | 0.81 | 0.65 |
| COMET (week 52) | 186/265 (70) | 170/265 (64) | 186/261 (71) | 28/265 (11) | 25/261 (10) | 36/261 (14) | 0.76 | 0.77 | 0.68 |
| TEMPO (week 52) | 135/229 (59) | 122/229 (53) | 133/229 (58) | 27/229 (12) | 16/229 (7) | 21/229 (9) | 0.76 | 0.86 | 0.82 |
| APPEAL (week 16) | 112/197 (57) | 77/197 (39) | 114/197 (58) | 45/197 (23) | 14/197 (7) | 47/197 (24) | 0.56 | 0.86 | 0.54 |
| LARA (week 24) | 158/279 (57) | 131/279 (47) | 159/279 (57) | 39/279 (14) | 25/279 (9) | 54/279 (19) | 0.72 | 0.82 | 0.62 |
| MTX groups | |||||||||
| COMET (week 52) | 125/263 (48) | 109/263 (41) | 120/253 (47) | 28/263 (11) | 28/253 (11) | 33/253 (13) | 0.79 | 0.78 | 0.74 |
| TEMPO (week 52) | 89/228 (39) | 69/228 (30) | 91/228 (40) | 28/228 (12) | 16/228 (7) | 36/228 (16) | 0.73 | 0.85 | 0.66 |
| DMARD plus MTX groups | |||||||||
| APPEAL (week 16) | 41/103 (40) | 19/103 (18) | 38/103 (37) | 22/103 (21) | 11/103 (11) | 23/103 (22) | 0.51 | 0.77 | 0.47 |
| LARA (week 24) | 20/142 (14) | 17/142 (12) | 19/142 (13) | 11/142 (8) | 3/142 (2) | 8/142 (6) | 0.66 | 0.91 | 0.75 |
*Remission and LDA were defined as <2.6 and ≤3.2 for DAS28 calculations and ≤3.3 and ≤11 for SDAI calculations.
†p<0.05 corresponds to κ coefficient of agreement between the two measurements.
‡PRESERVE patients received open-label ETN 50 mg plus MTX only.
DAS28-CRP, Disease Activity Score in 28 joints calculated with C-reactive protein; DAS28-ESR, Disease Activity Score in 28 joints calculated with erythrocyte sedimentation rate; DMARD, disease-modifying antirheumatic drugs; ETN, etanercept; LDA, low disease activity; MTX, methotrexate; SDAI, Simplified Disease Activity Index.